On February 25, 2022 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022 (Press release, Molecular Partners, FEB 25, 2022, View Source [SID1234609082]). In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Cowen Health Care Conference – Fireside chat

Wednesday, March 9, 2022 at 2:10-2:40pm ET
Conference Participation Details:

Credit Suisse London Global Healthcare Conference

Tuesday, March 1, 2022 to Wednesday, March 2, 2022
Webcasted presentations will be made available through the Molecular Partners website.